story of the week
Lapatinib With Trastuzumab for HER2-Positive Early Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Lapatinib With Trastuzumab for HER2-Positive Early Breast Cancer (NeoALTTO): Survival Outcomes of a Randomised, Open-Label, Multicentre, Phase 3 Trial and Their Association With Pathological Complete Response
Lancet Oncol 2014 Sep 01;15(10)1137-46, E de Azambuja, AP Holmes, M Piccart-Gebhart, E Holmes, S Di Cosimo, RF Swaby, M Untch, C Jackisch, I Lang, I Smith, F Boyle, B Xu, CH Barrios, EA Perez, HA Azim, SB Kim, S Kuemmel, CS Huang, P Vuylsteke, RK Hsieh, V Gorbunova, A Eniu, L Dreosti, N Tavartkiladze, RD Gelber, H Eidtmann, J BaselgaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.